The antibiotic pipeline: reviving research and development and speeding drugs to market

Expert Review of Anti-Infective Therapy

Volumn 15, Issue 5, 2017, Pages 425-433

  Luepke, Katherine H ^a   Mohr, John F ^a  

^a Medical Affairs Strategic Solutions LLC   (United States)

Author keywords

Antibacterial; antibiotic; antimicrobial resistance; development; pipeline; research

Indexed keywords

ANTIBIOTIC AGENT; NEW DRUG; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG APPROVAL; DRUG INDUSTRY; DRUG INFORMATION; DRUG LEGISLATION; DRUG MARKETING; DRUG RESEARCH; DRUG SCREENING; DRUG SYNTHESIS; FOOD AND DRUG ADMINISTRATION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; MULTIDRUG RESISTANCE; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PUBLIC-PRIVATE PARTNERSHIP; REVIEW; BACTERIAL INFECTIONS; DRUG DEVELOPMENT; ECONOMICS; LEGISLATION AND JURISPRUDENCE; PROCEDURES; SYNTHESIS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG DISCOVERY; DRUG INDUSTRY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUGS, INVESTIGATIONAL; HUMANS; PHARMACEUTICAL RESEARCH;

EID: 85017418747     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1080/14787210.2017.1308251     Document Type: Review

References (62)

1. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States 2013 [May 26, 2016]. Available from:http://www.cdc.gov/drugresistance/threat-report-2013/.
2. McNeill RND, Abutaleb Y., Reuters Investigates:The Uncounted:The deadly epidemic America is ignoring. October 31, 2016. Available from:http://www.reuters.com/investigates/special-report/usa-uncounted-surveillance/#sidebar-abrcdc-space.
3. Review on Antimicrobial Resistance. Securing New Drugs for Future Generations:The Pipeline of Antibiotics 2015 May26, 2016. Available from:http://amr-review.org/sites/default/files/SECURING%20NEW%20DRUGS%20FOR%20FUTURE%20GENERATIONS%20FINAL%20WEB_0.pdf.
4. Shlaes DMSD, Opiela C, Spellberg B., The FDA Reboot of Antibiotic Development. Antimicrob Agents Chemother. 2013;57:4605–4607.
5. Cooper MASD. Fix the antibiotics pipeline. Nature. 2011;472:32.
6. Luepke KH, Suda KJ, Boucher H, et al. Past, Present, and Future of Antibacterial Economics:Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications. Pharmacotherapy. 2017;37:71–84. Epub 2016/11/20.
7. Spellberg B. The future of antibiotics. Crit Care. 2014;18:228.
8. Payne DJ, Miller LF, Findlay D, et al. Time for a change:addressing R&D and commercialization challenges for antibacterials. Philos Trans R Soc Lond B Biol Sci. 2015;370:20140086.
9. The Pew Charitable Trusts:A Scientific Roadmap for Antibiotic Discovery 2016 January26, 2017. Available from:http://www.pewtrusts.org/en/research-and-analysis/reports/2016/05/a-scientific-roadmap-for-antibiotic-discovery.
10. Institute of Medicine (IOM). Antibiotic Resistance:Implications for Global Health and Novel Intervention Strategies:Workshop Summary. Washington, DC:The National Academies Press; 2010.
11. The Pew Charitable Trusts:The Critical Need for New Antibiotics January 26, 2017. Available from:http://www.pewtrusts.org/en/multimedia/data-visualizations/2016/the-critical-need-for-new-antibiotics.
12. Projan SJSD. Antibacterial drug discovery:is it all downhill from here? Clin Microbiol Infect. 2004;10:18–22.
13. Projan SJ. Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol. 2003;6:427–430.
14. Sertkaya AEJ, Birkenbach A, Franz C, et al. Analytical Framework for Examining the Value of Antibacterial Products. Lexington, MA:Eastern Research Group;2014 April 15. HHSP23337004T.
15. Dollar Times Inflation Calculator [May 26, 2016]. Available from:http://www.dollartimes.com/calculators/inflation.htm.
16. Knirsch C, Alemayehu D, Botgros R, et al., Improving Conduct and Feasibility of Clinical Trials to Evaluate Antibacterial Drugs to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia:Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team. Clin Infect Dis. 2016;63Suppl 2:S29–36. Epub 2016/08/03.
17. Madre L, Tenaerts P, How Public-Private Collaborations Are Driving Solutions to the Antibacterial Drug Development Crisis. Clin Infect Dis. 2016;63Suppl 2:S25–6. Epub 2016/08/03.
18. Stergiopoulos STP, Gets KA, Brown C, et al. Cost Drivers of a Hospital Acquired Bacterial Pneumonia and Ventilator Acquired Bacterial Pneumonia (HABP/VABP) Phase Three Clinical Trials. San Diego, CA:Publisher; 2015. [October9, 2015].
19. Barriere SL, Challenges in the design and conduct of clinical trials for hospital-acquired pneumonia and ventilator-associated pneumonia:an industry perspective. Clin Infect Dis. 2010;51Suppl 1:S4–9. Epub 2010/07/06.
20. Talbot GH. Considerations in undertaking a clinical development program for hospital-acquired bacterial pneumonia and/or ventilator-associated bacterial pneumonia. Clin Infect Dis. 2010;51(Suppl 1):S144–9.
21. Guh AY, Bulens SN, Mu Y, et al. Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013. JAMA. 2015;314:1479–1487.
22. McDonnell A, Rex JH, Goossens H, et al., Efficient Delivery of Investigational Antibacterial Agents via Sustainable Clinical Trial Networks. Clin Infect Dis. 2016;63Suppl 2:S57–9. Epub 2016/08/03.
23. Achaogen, Inc. Achaogen Announces Positive Results in Phase 3 cUTI and CRE Clinical Trials of Plazomicin 2016 [cited 2017 January27, 2017]. Available from:http://investors.achaogen.com/releasedetail.cfm?ReleaseID=1003671.
24. Shionogi I. Shionogi Announces Positive Top-Line Results for Cefiderocol Pivotal cUTI Clinical Trial 2017 [January27, 2017]. Available from:http://www.shionogi.com/newsroom/article.html#122507.
25. Merck Sharp & Dohme Corp. Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium + Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013) (RESTORE-IMI 1) 2016 [cited 2017 January27, 2017]. Available from:https://clinicaltrials.gov/ct2/show?term=relebactam&rank=1.
26. Merck Sharp & Dohme Corp. Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014) (RESTORE-IMI 2) 2016 [cited 2017 January27, 2017]. Available from:https://clinicaltrials.gov/ct2/show/NCT02493764?term=relebactam&rank=2.
27. The Medicines Company. FDA Grants Fast Track Status for Investigational Antibiotic CARBAVANCE® (meropenem-vaborbactam) 2016 [January27, 2017]. Available from:http://www.themedicinescompany.com/investors/news/fda-grants-fast-track-status-investigational-antibiotic-carbavance%C2%AE-meropenem.
28. Innovative Medicines Initiative:New Drugs for Bad Bugs [cited 2016 May 26]. Available from:http://www.imi.europa.eu/content/nd4bb.
29. Review on Antimicrobial Resistance:Tackling Drug-Resistant Infections Globally:Final Report and Recommendations 2016 May19, 2016. Available from:http://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf.
30. National Action Plan for Combating Antibiotic-Resistant Bacteria. Washington:White House. DC2015. https://obamawhitehouse.archives.gov/sites/default/files/docs/national_action_plan_for_combating_antibotic-resistant_bacteria.pdf
31. Global Action Plan on Antimicrobial Resistance. Geneva, Switzerland:World Health Organization; 2015. http://www.wpro.who.int/entity/drug_resistance/resources/global_action_plan_eng.pdf
32. NIAID’s Antibacterial Resistance Program:Current Status and Future Directions. Washington, DC:Department of Health and Human Services; 2014. https://www.niaid.nih.gov/sites/default/files/arstrategicplan2014.pdf
33. The Pew Charitable Trusts. New Federal Funds Support Targeted Research on Toughest Superbugs 2017 [cited 2017 January27, 2017]. Available from:http://www.pewtrusts.org/en/research-and-analysis/analysis/2017/01/09/new-federal-funds-support-targeted-research-on-toughest-superbugs.
34. US Department of Health and Human Services. Partnerships for the Development of Tools to Advance Therapeutic Discovery for Select Antimicrobial-Resistant Gram-Negative Bacteria (R01) 2016 [cited 2017 January27, 2017]. Available from:https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-16-081.html.
35. Antibacterial Resistance Leadership Group [May 26, 2016]. Available from:http://www.arlg.org/.
36. Eichberg MJ. Public funding of clinical-stage antibiotic development in the United States and European Union. Health Secur. 2015;13:156–165.
37. CARB-X:Xccelerating global antibacterial innovation. [November 8, 2016]. Available from:www.carb-x.org.
38. Innovative Medicines Initiative New Drugs for Bad Bugs. The Innovative Medicines Initiative response to antimicrobial resistance2016 [May 2016]; 2017. Available from:http://www.imi.europa.eu/sites/default/files/uploads/documents/Publications/IMIandAMR_factsheet_vMay2016.pdf.
39. Clinical Trials Transformation Initiative:Antibacterial Drug Development (ABDD) 2017 [cited 2017 January27, 2017]. Available from:https://www.ctti-clinicaltrials.org/programs/antibacterial-drug-development.
40. E K. Taking the mystery out of expedited approvals2015 2017 [cited January27, 2017]. Available from:http://weinberggroup.com/fda-expedited-approvals/.
41. Somerville SHKJ, FDA’s Expedited Review Process:The Need for Speed. Applied Clinical Trials [Internet]. 2015 January27, 2017. Available from:http://www.appliedclinicaltrialsonline.com/fda-s-expedited-review-process-need-speed.
42. Hwang TJ, Kesselheim AS. Leveraging Novel and Existing Pathways to Approve New Therapeutics to Treat Serious Drug-Resistant Infections. Am J Law Med. 2016;42:429–450.
43. Deak D, Outterson K, Powers JH, et al. Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug Administration-Approved Antibiotics, 2010-2015. Ann Intern Med. 2016;165:363–372. Epub 2016/05/31.
44. US Food and Drug Administration. CDER Breakthrough Therapy Designation Approvals 2016 [cited 2017 January27, 2017]. Available from:http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/NDAandBLAApprovalReports/UCM481542.pdf.
45. US Food and Drug Administration. CDER Drug and Biologic Accelerated and Restricted Distribution Approvals 2017 [cited January27, 2017]. Available from:http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/NDAandBLAApprovalReports/UCM404466.pdf.
46. Generating Antibiotic Incentives Now (GAIN) Act. In:112th Congress, United States of America, ed. S. 3187, Title VIII; 2012.
47. 21st Century Cures Act. Sect. 3042 (2016).
48. Rex JH, Eisenstein BI, Alder J, et al. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect Dis. 2013;13:269–275.
49. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry:Antibacterial Therapies for Patients with Unmet Medical Need for the Treatment of Serious Bacterial Diseases (Draft Guidance). 2013. https://www.fda.gov/downloads/Drugs/Guidances/UCM359184.pdf
50. European Medicines Agency. Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products. 2016. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC500210982.pdf
51. Muller AE, Theuretzbacher U, Mouton JW. Use of old antibiotics now and in the future from a pharmacokinetic/pharmacodynamic perspective. Clin Microbiol Infect. 2015;21:881–885. Epub 2015/06/21.
52. Moore TJ, Furberg CD. The safety risks of innovation:The fda’s expedited drug development pathway. JAMA. 2012;308:869–870.
53. Mendoza RL. The 21st Century Cures Act:pharmacoeconomic boon or bane?. J Med Econ. 2017 Apr;20(4):315-317.
54. Holland TL, Mikita S, Bloom D, et al. Patient and physician attitudes regarding risk and benefit in streamlined development programmes for antibacterial drugs:a qualitative analysis. BMJ Open. 2016 Nov 10;6(11):e013561.
55. Van Boeckel TP, Gandra S, Ashok A, et al. Global antibiotic consumption 2000 to 2010:an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014;14:742–750.
56. Van Boeckel TP, Brower C, Gilbert M, et al. Global trends in antimicrobial use in food animals. Proc Natl Acad Sci USA. 2015;112:5649–5654.
57. The Pew Charitable Trusts. Tracking the Pipeline of Antibiotics in Development 2017 [cited January27, 2017]. Available from:http://www.pewtrusts.org/en/research-and-analysis/collections/2016/12/tracking-the-pipeline-of-antibiotics-in-development.
58. BIO Industry Analysis. Clinical Development Success Rates 2006-2015. 2016 [09March 2017]. Available from:https://www.bio.org/sites/default/files/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf.
59. Gupta V, Olesky M, Tabak YP, et al. National prevalence of carbapenem-resistant Enterobacteriaceae (CRE) in the ambulatory and acute care settings in the United States in 2015-2016. Poster 352, ID Week 2016, New Orleans, LA, October26-30, 2016.
60. Thaden JT, Lewis SS, Hazen KC, et al. Rising rates of carbapenem-resistant enterobacteriaceae in community hospitals:a mixed-methods review of epidemiology and microbiology practices in a network of community hospitals in the southeastern United States. Infect Control Hosp Epidemiol. 2014;35:978–983. Epub 2014/07/16.
61. Report MW. Vital Signs:CRE. MMWR Morbidity and mortality weekly report. 2013;62:157–160.
62. Czaplewski L, Bax R, Clokie M, et al. Alternatives to antibiotics—a pipeline portfolio review. Lancet Infect Dis. 2016;16:239–251.